LifeMD (LFMD) Stock Price, News & Analysis

Company Overview

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care. Patients access virtual consultations, follow-up visits and medication management through a flat-fee membership model. Specialized programs address conditions such as erectile dysfunction, hair loss, thyroid disorders and metabolic health, while integrated pharmacy partnerships allow users to receive prescribed treatments directly at home.

Since its founding, LifeMD has expanded through strategic acquisitions of complementary telehealth businesses to broaden its clinical capabilities and patient reach. The company’s brands now encompass platforms focused on preventive care, chronic disease management and women’s health, creating a multi-specialty virtual care network. LifeMD serves patients across the United States and continually invests in digital technology to improve care coordination and patient engagement.

Headquartered in Florida, LifeMD went public in early 2021 and trades on the Nasdaq under the ticker LFMD. The company is led by a management team with deep experience in healthcare delivery, digital innovation and telemedicine. LifeMD continues to leverage its unified platform to address evolving consumer preferences for accessible, cost-effective virtual care.

Key Stats

• Today's Range: $5.99 to $6.25
• 50-Day Range: $5.80 to $12.35
• 52-Week Range: $3.99 to $15.84
• Volume: 1.25 million shs
• Average Volume: 1.18 million shs
• Market Capitalization: $288.31 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $13.17
• Consensus Rating: Moderate Buy

LifeMD Stock Analysis - MarketRank™

LifeMD scored higher than 69% of companies evaluated by MarketBeat, and ranked 306th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

LifeMD has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.

Upside Potential

LifeMD has a consensus price target of $13.17, representing about 116.6% upside from its current price of $6.08.

Amount of Analyst Coverage

LifeMD has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for LifeMD are expected to grow in the coming year, from ($0.56) to $0.12 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LifeMD is -28.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LifeMD is -28.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

15.01% of the float of LifeMD has been sold short.

Short Interest Ratio / Days to Cover

LifeMD has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LifeMD has recently decreased by 10.83%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LifeMD does not currently pay a dividend.

Dividend Growth

LifeMD does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

15.01% of the float of LifeMD has been sold short.

Short Interest Ratio / Days to Cover

LifeMD has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in LifeMD has recently decreased by 10.83%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.15

News Sentiment

LifeMD has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 30 news articles for LifeMD this week, compared to 5 articles on an average week.

Search Interest

26 people have searched for LFMD on MarketBeat in the last 30 days. This is an increase of 117% compared to the previous 30 days.

MarketBeat Follows

3 people have added LifeMD to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, LifeMD insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,479,000.00 in company stock.

Percentage Held by Insiders

18.40% of the stock of LifeMD is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 35.52% of the stock of LifeMD is held by institutions.

LFMD Stock Analysis - Frequently Asked Questions

How have LFMD shares performed this year?

LifeMD's stock was trading at $4.95 at the beginning of the year. Since then, LFMD stock has increased by 22.8% and is now trading at $6.08.

How were LifeMD's earnings last quarter?

LifeMD, Inc. (NASDAQ:LFMD) announced its quarterly earnings data on Tuesday, May, 6th. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.05. The business earned $65.70 million during the quarter, compared to analysts' expectations of $62.47 million.
Read the conference call transcript.

Who are LifeMD's major shareholders?

LifeMD's top institutional shareholders include Connor Clark & Lunn Investment Management Ltd. (2.04%), Geode Capital Management LLC (2.04%), Jump Financial LLC (1.09%) and Arrowstreet Capital Limited Partnership (0.92%). Insiders that own company stock include Justin Schreiber, Nicholas P Alvarez, Bertrand Velge, Marc David Benathen, Jessica Friedeman, Stefan Galluppi and Eric Harold Yecies.
View institutional ownership trends.

How do I buy shares of LifeMD?

Shares of LFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of LifeMD own?

Based on aggregate information from My MarketBeat watchlists, some other companies that LifeMD investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 9/17/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:LFMD
• CIK: 948320
• Web: www.lifemd.com
• Phone: (866) 351-5907
• Fax: N/A
• Employees: 230
• Year Founded: N/A

Price Target and Rating

• Average Price Target for LifeMD: $13.17
• High Price Target: $18.00
• Low Price Target: $7.00
• Potential Upside/Downside: +117.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.88
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.88 million
• Net Margins: -2.41%
• Pretax Margin: -1.83%
• Return on Equity: N/A
• Return on Assets: -8.11%

Debt

• Debt-to-Equity Ratio: 9.21
• Current Ratio: 0.77
• Quick Ratio: 0.72

Sales & Book Value

• Annual Sales: $212.45 million
• Price / Sales: 1.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.09) per share
• Price / Book: -67.30

Miscellaneous

• Outstanding Shares: 47,420,000
• Free Float: 38,692,000
• Market Cap: $287.22 million
• Optionable: Optionable
• Beta: 1.56